Rapamycin in fibrotic diseases: beneficial or detrimental agent?
- Author:
Xue-Feng XU
1
;
Hua-Ping DAI
Author Information
1. Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
- Publication Type:Journal Article
- MeSH:
Fibrosis;
drug therapy;
metabolism;
Humans;
Immunosuppressive Agents;
therapeutic use;
Models, Biological;
Sirolimus;
therapeutic use
- From:
Chinese Medical Journal
2013;126(7):1364-1369
- CountryChina
- Language:English
